淋巴细胞/单核细胞比值对恶性肿瘤患者预后评估的研究进展

doi:10.11904/j.issn.1002-3070.2017.02.019

摘要/Abstract

摘要： 炎症在肿瘤的发生及发展中起着重要的作用,淋巴细胞和单核细胞是炎症反应的关键免疫细胞,可以反映机体免疫状态。近年来,越来越多的临床研究显示肿瘤患者治疗前外周血淋巴细胞/单核细胞比值(Lymphocyte-to-monocyte ratio,LMR)可能对评价患者的预后存在一定的价值。LMR对于头颈部肿瘤、食管癌、乳腺癌、卵巢癌、肺癌、胃癌、结直肠癌等恶性肿瘤预后价值已经得到证实。本文就LMR在恶性肿瘤患者对评价预后的价值方面做一综述。

关键词: 淋巴细胞/单核细胞比值, 肿瘤, 预后, 炎性因子

Abstract: Inflammation has a critical role in the pathogenesis and progression of cancer.lymphocyte and monocyte play an important role in inflammatory reaction,reflecting body immune status.In recent years,more and more clinical studies have shown that pretreatment of lymphocyte-to-monocyte ratio(LMR)in the patients with malignant tumor may have a certain value in evaluating the prognosis of cancer patients such as nasopharyngeal cancer,esophageal cancer,breast cancer,ovarian cancer,lung cancer,gastric cancer,colorectal cancer,etc.This article reviews the latest research progress on the value of LMR in the evaluation of the prognosis of the patients with malignant tumor.

Key words: Lymphocyte-to-monocyte ratio, Tumors, Prognosis, Inflammatory factor

中图分类号:

张爱岐, 金时, 曹守波(综述), 于雁(审校). 淋巴细胞/单核细胞比值对恶性肿瘤患者预后评估的研究进展[J]. 实用肿瘤学杂志, 2017, 31(2): 188-192.

ZHANG Aiqi,JIN Shi,CAO Shoubo,YU Yan. Prognostic value of lymphocyte-to-monocyte ratio in the patients with malignant tumor[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 188-192.

参考文献

1 Deng Q,He B,Liu X,et al.Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model[J].J Transl Med,2015,13(1):66-81.
2 Li J,Lin J,Luo Y,et al.Multivariate analysis of prognostic biomarkers in surgically treated endomertial cancer[J].PLoS One,2015,10(6):e0130640.
3 Hasenclever D,Diehl V.A prognostic score for advanced Hodgkin′s disease.International Prognostic Factors Project on Advanced Hodgkin′s Disease[J].N Engl J Med,1998,339(21):1506-1514.
4 Ray-Coquard I,Cropet C,Van Glabbeke M,et al.Lymphopenia as a prognostic factor for overall survival in advanced carcinomas,sarcomas,and lymphomas[J].Cancer Res,2009,69(13):5383-5391.
5 Ceze N,Thibault G,Goujon G,et al.Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy[J].Cancer Chemother Pharmacol,2011,68(5):1305-1313.
6 Chanmee T,Ontong P,Konno K,et al.Tumor-associated macrophages as major players in the tumor microenvironment[J].Cancers(Basel),2014,6(3):1670-1690.
7 Schmidt H,Bastholt L,Geertsen P,et al.Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma:a prognostic model[J].Br J Cancer,2005,93(3):273-278.
8 Lee YY,Choi CH,Sung CO,et al.Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer:comparison with SCC-Ag level[J].Gynecol Oncol,2012,124(1):92-97.
9 Koh YW,Shin SJ,Park C,et al.Absolute monocyte count predicts overall survival in mantle cell lymphomas:correlation with tumour-associated macrophages[J].Hematol Oncol,2014,32(4):178-186.
10 Li ZM,Huang JJ,Xia Y,et al.Blood lymphocyte-tomonocyteratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP[J].PLoS One,2012,7(7):e41658.
11 Porrata LF,Ristow K,Colgan JP,et al.Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin′s lymphoma[J].Haematologica,2012,97(2):262-269.
12 Man YG,Stojadinovic A,Mason J,et al.Tumor-infiltrating immune cells promoting tumor invasion and metastasis:existingtheories[J].J Cancer,2013,4(1):84-95.
13 Tsutsui S,Yasuda K,Suzuki K,et al.Macrophage infiltration and its prognostic implications in breast cancer:the relationshipwith VEGF expression and microvessel density[J].Oncol Rep,2005,14(2):425-431.
14 Steidl C,Lee T,Shah SP,et al.Tumor-associated macrophages and survival in classic Hodgkin′s lymphoma[J].N Engl J Med,2010,362(10):875-885.
15 Liao Q,Zeng Z,Guo X,et al.LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation[J].Oncogene,2014,33(16),2098-2109.
16 Liao Q,Guo X,Li X,et al.Analysis of the contribution of nasopharyngeal epithelial cancer cells to the induction of a local inflammatory response[J].J Cancer Res Clin Oncol,2011,138(1):57-64.
17 Li J,Jiang R,Liu WS,et al.A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma[J].PLoS One,2013,8(12):e83069.
18 Lin GN,Peng JW,Liu DY,et al.Increased lymphocyte to monocyte ratio is associated with better prognosis in patients with newly diagnosed metastatic nasopharyngeal carcinoma receiving chemotherapy[J].Tumor Biology,2014,35(11):10849-10854.
19 Ni XJ,Zhang XL,Ou-Yang QW,et al.An elevated peripheral blood lymphocyte-to-monocyte ratio predicts favorable response and prognosis in locally advanced breast cancer following neoadjuvant chemotherapy[J].PLoS One,2014,9(11):e111886.
20 吴朔,姜翠,徐君南,等.淋巴细胞/单核细胞比值在三阴性乳腺癌预后评估中的临床研究[J].现代预防医学,2016,43(15):2855-2858.
21 王秀娟,苑中甫,邱海峰,等.术前外周血淋巴细胞/单核细胞比值与上皮性卵巢癌患者预后的关系[J].现代妇产科进展,2016,9(25):654-657.
22 Hu P,Shen H,Wang G,et al.Prognostic significance of systemic inflammation-based lymphocyte-monocyte ratio in patients with lung cancer:based on a large cohort study[J].PLoS One,2014,9(9):e108062.
23 Go SI,Kim RB,Song HN,et al.Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer[J].Med Oncol,2014.31(12):323-329.
24 Heinemann V,von Weikersthal LF,Decker T,et al.FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer(FIRE-3):a randomised,open-label,phase 3 trial[J].Lancet Oncol 2014,15(10):1065-1075.
25 Grothey A,Sugrue MM,Purdie DM,et al.Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer:results from a large observational cohort study(BRiTE)[J].J Clin Oncol,2008,26(33):5326-5334.
26 Shibutani M,Maeda K,Nagahara H,et al.Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer[J].World J Gastroenterol,2015,21(34):9966-9973.
27 Fong Y,Fortner J,Sun RL,et al.Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer:analysis of 1001 consecutive cases[J].Ann Surg,1999,230(3):309-321.
28 John SK,Robinson SM,Rehman S,et al.Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy:an 11-year single-centre study[J].Dig Surg,2013,30(4-6):293-301.
29 Tomlinson JS,Jarnagin WR,DeMatteo RP,et al.Actual 10-year survival after resection of colorectal liver metastases defines cure[J].J Clin Oncol,2007,25(29):4575-4580.
30 Neofytou K,Smyth EC,Giakoustidis A,et al.The preoperative lymphocyte-to-monocyte ratio is prognostic of clinical outcomes for patients with liver-only colorectal metastases in the neoadjuvant setting[J].Ann Surg Oncol,2015,22(13):4353-4362.

[1]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.
[2]	张佳文,于雁,张薇,曹京燕,罗雯,尚利华. 基于UPLC-TOF/MS的小细胞肺癌患者血清代谢组学研究[J]. 实用肿瘤学杂志, 2019, 33(3): 200-205.
[3]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[4]	张茂祥,孙惠昕,宋冰冰. 2008—2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.
[5]	刘乙澍,曲国蕃. 长链非编码RNA在骨肉瘤中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 266-270.
[6]	侯玉雪,李晓莉. Wnt7a与恶性肿瘤的关系及研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 271-275.
[7]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[8]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[9]	徐晖, 李希, 周春水. 应用以人转录组为靶点的shRNA文库筛选肺癌肿瘤相关抑制基因[J]. 实用肿瘤学杂志, 2019, 33(2): 97-102.
[10]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[11]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[12]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[13]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[14]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[15]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.